Results 1 to 10 of about 212 (47)

Genetic basis of anthracyclines cardiotoxicity: Literature review [PDF]

Acta Biomedica Scientifica, 2021
The purpose of this review was to systematize data on molecular genetic markers of increased risk of cardiotoxic effects, as well as to search for risk and protective variants of candidate genes.
M. Yu. Sinitsky, A. V. Tsepokina, M. V. Khutornaya, A. V. Ponasenko, A. N. Sumin   +4 more
doaj   +3 more sources

Assessment of left ventricular diastolic dysfunction following anthracyclinebased chemotherapy in breast cancer patients

Acta Biomedica Scientifica, 2022
Cardiotoxicity is a side effect of anthracycline-based chemotherapy. Clinical and prognostic significance of left ventricular diastolic dysfunction in heart failure patients is undeniable.The aim.
A. N. Sumin, A. V. Shcheglova, Yu. S. Slepynina, A. V. Ivanova, O. M. Polikutina   +4 more
doaj   +1 more source

РОЛЬ ПОЛИМОРФИЗМОВ ГЕНОВ TTN, TTN-TRUNCATION, ММР-2, ММР-3 В РАЗВИТИИ АНТРАЦИКЛИН-ИНДУЦИРОВАННОЙ КАРДИОМИОПАТИИ

Žurnal Grodnenskogo Gosudarstvennogo Medicinskogo Universiteta, 2021
В обзоре рассматривается актуальная проблема кардиотоксичности химиопрепаратов. Противоопухолевые антибиотики антрациклины способны вызывать кардиомиoпатию, которая может ухудшать прогноз у онкопациентов и быть самостоятельной причиной смерти.
I. A. Karputs, V. A. Snezhitskiy, M. N. Kurbat, A. Yu. Rubinskiy, T. A. Smirnova   +4 more
doaj   +1 more source

CIRCULATION MICRORNA AS A POSSIBLE PREDICTOR OF ANTHRACYCLINE-INDUCED CARDIOTOXICITY

Байкальский медицинский журнал, 2023
Introduction. Doxorubicin is an anthracycline antibiotic widely used in the treatment of malignant neoplasms. Anthracyclines have been shown to have an undesirable side effect associated with the development of cardiotoxic effects.
Maria Vladimirovna Khutornaya, Anna Victorovna Sinitskaya, Anna Victorovna Shcheglova, Alexei Nikolaevich Sumin, Anastasia Valerievna Ponasenko   +4 more
doaj   +1 more source

Современные подходы к системному лечению BRCA-ассоциированного трижды негативного рака молочной железы [PDF]

, 2023
BRCA-associated triple-negative breast cancer (TNBC) is characterized by high sensitivity to DNA-damaging cytotoxic drugs. The use of well-known BRCA1/2-specific antitumor agents – platinum derivatives and PARP inhibitors – has been discussed for a long ...
D. A. Enaldieva, E. K. Zhiltsova, E. N. Imyanitov, L. F. Shaikhelislamova, L. P. Gigolaeva, P. V. Krivorotko, R. V. Donskikh, V. F. Semiglazov, В. Ф. Семиглазов, Д. А. Еналдиева, Е. К. Жильцова, Е. Н. Имянитов, Л. П. Гиголаева, Л. Ф. Шайхелисламова, П. В. Криворотько, Р. В. Донских   +15 more
core   +4 more sources

High-sensitivity troponin I as a predictor of left ventricular dysfunction in the use of cardiotoxic anticancer agents for breast cancer in patients with predominantly low and moderate risk of cardiotoxicity [PDF]

, 2022
Aim. To study the significance of monitoring high-sensitivity troponin I (hs-cTnI) for predicting anthracycline-induced left ventricular (LV) dysfunction in the treatment of breast cancer in patients with moderate and low risk of cardiotoxicity (CT ...
A. A. Meshcheryakov, A. A. Shmeleva, A. N. Gerasimov, A. R. Levshina, D. S. Valiulina, L. V. Bolotina, M. G. Poltavskaya, O. V. Andreeva, P. Sh. Chomakhidze, T. I. Deshkina, V. D. Levina, V. P. Sedov, Z.Z.A. Fashafsha   +12 more
core   +3 more sources

Cardioprotective effect of thiotriazoline in cancer patients [PDF]

, 2023
Aim. To evaluate the effectiveness of morpholinium-methyl-triazolyl-thioacetate (thiotriazoline) as a cardioprotector in patients with non-Hodgkin’s lymphomas who received chemotherapy with the inclusion of anthracyclines.Material and methods.
A. V. Koltsov, V. V. Tyrenko
core   +2 more sources

Cell biobank as a necessary infrastructure for the development and implementation of mesenchymal stem cell-based therapy in the treatment of anthracycline-induced cardiotoxicity. Literature review and own data

Кардиоваскулярная терапия и профилактика, 2020
Cardiovascular diseases, along with cancer, are the leading causes of death worldwide. Although modern pharmacological treatment of various cardiomyopathies can slow the development of myocardial dysfunction, they have limited effectiveness in patients ...
L. Yu. Grivtsova, O. E. Popovkina, N. N. Dukhova, O. A. Politiko, V. V. Yuzhakov, L. A. Lepekhina, S. Sh. Kalsina, S. A. Ivanov, A. D. Kaprin   +8 more
doaj   +1 more source

Антрациклины в лечении солидных опухолей у детей [PDF]

, 2015
Aim: analysis of literary data on the use of anthracyclines in the treatment of solid tumors in children.Methods: Review of the literature on the use of anthracyclines in the treatment of solid tumors in children.
Белецкий, Владимир Евгеньевич
core   +6 more sources

Cardioprotective Strategies for Doxorubicin-induced Cardiotoxicity: Present and Future [PDF]

, 2022
The improvement of drugs and protocols of chemotherapeutic treatment has led to improved outcomes and survival in patients with cancer. But along with this, at first glance a positive point, there was another interdisciplinary problem, which is the need ...
A. M. Chaulin, D. V. Duplyakov
core   +2 more sources